The BC Cancer Personalized OncoGenomics (POG) Program, co-led by BC Cancer Medical Oncologist Dr. Janessa Laskin and Dr. Marco Marra, Director of Canada's Michael Smith Genome Sciences Centre at BC Cancer, is a patient-centric research initiative, consisting of oncologists, pathologists and other clinical, research, and technical personnel, studying the impact of embedding whole genome and transcriptome analysis into the clinical care of B.C. patients with advanced cancers.
POG is a world-leading research program that is using intensive genomic data collection and analysis to identify and better understand the genomic alterations that drive cancer growth, metastasis, and the biological evolution and response to therapies. Integration of genomic, transcriptomic, clinical, and treatment data provides a rich dataset for the interrogation and understanding of correlates of treatment response and resistance.
Analysis of the data from the first 570 patients, published in the April 2020 issue of Nature Cancer and featured on its cover, has demonstrated the impacts of therapy on cancer genomes and the potential for precision oncology to provide more effective therapeutic options for advanced cancer patients.